A bottle of Johnson & Johnson branded lotion will be sold at a pharmacy in Salt Lake City, Utah on Thursday, February 25, 2021.
George Frey | Bloomberg | Getty Images
Morgan Stanley says investors should look to Johnson & Johnson for its diversified growth and relatively cheap valuation.
The company was in focus last year due to the development of a Covid-19 vaccine, but the stock wasn’t a big winner. The share rose by almost 15% in the past year.
Analyst David Risinger assumed that the stock would be covered with an overweight rating.